0000950170-24-138138.txt : 20241218 0000950170-24-138138.hdr.sgml : 20241218 20241218205609 ACCESSION NUMBER: 0000950170-24-138138 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20241216 FILED AS OF DATE: 20241218 DATE AS OF CHANGE: 20241218 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Gangloff Scott A. CENTRAL INDEX KEY: 0001663253 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38944 FILM NUMBER: 241560755 MAIL ADDRESS: STREET 1: C/O ONCOBIOLOGICS, INC. STREET 2: 7 CLARKE DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Akero Therapeutics, Inc. CENTRAL INDEX KEY: 0001744659 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 601 GATEWAY BOULEVARD, SUITE 350 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-487-6488 MAIL ADDRESS: STREET 1: 601 GATEWAY BOULEVARD, SUITE 350 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 ownership.xml 4 X0508 4 2024-12-16 0001744659 Akero Therapeutics, Inc. AKRO 0001663253 Gangloff Scott A. C/O AKERO THERAPEUTICS, INC. 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080 false true false false Chief Technology Officer false Common Stock 2024-12-16 4 A false 24300 0 A 24300 D Stock Option (Right to Buy) 29.23 2024-12-16 4 A false 73700 0 A 2034-12-15 Common Stock 73700 73700 D These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in eight (8) equal semi-annual installments, commencing from December 16, 2024, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. This option shall vest and become exercisable in forty-eight (48) equal monthly installments, commencing from December 16, 2024, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. /s/ Jonathan Young, Attorney-in-Fact 2024-12-18